BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,772 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Follow-Up Questions
What is the price performance of BNTX stock?
The current price of BNTX is $103.7, it has decreased 0.24% in the last trading day.
What are the primary business themes or industries for Biontech SE?
Biontech SE belongs to Biotechnology industry and the sector is Health Care
What is Biontech SE market cap?
Biontech SE's current market cap is $24.9B
Is Biontech SE a buy, sell, or hold?
According to wall street analysts, 24 analysts have made analyst ratings for Biontech SE, including 7 strong buy, 14 buy, 7 hold, 0 sell, and 7 strong sell
